A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody is a phase 3, interventional study registered as NCT06048315 by Degan Lu, with a registry enrolment figure of 52 participants, started 2023-09 and due to reach its primary completion in 2026-06. Interventions recorded: Anlotinib; Penpulimab. Conditions listed: Lung Cancer; TKI Resistance; EGFR Sensitive Mutation; Anlotinib; Pianzumab. Primary outcome: Progress Free Survival. Lung eligibility wording from the registry: "* According to the International Association for the Study of Lung Cancer and the Joint Committee on the American Classification of Cancer, 8th edition TNM staging of lung cancer, locally advanced or metastatic (IIIB, IIIC, IV) NSCLC patients who are confirmed by histology or cytology to be inoperab". No results are recorded here; the registry entry is the source.